Market Exclusive

Analyst Upgrades – Dova Pharmaceuticals (NASDAQ:DOVA) Stock Gets Upgraded By Leerink Swann from Market Perform to Outperform

Analyst Ratings For Dova Pharmaceuticals (NASDAQ:DOVA)

Today, Dova Pharmaceuticals (NASDAQ:DOVA) stock received an upgrade by Leerink Swann from Market Perform to Outperform.

There are 3 buy ratings on the stock.

The current consensus rating on Dova Pharmaceuticals (NASDAQ:DOVA) is Buy (Score: 3.00) with a consensus target price of $29.67 per share, a potential 32.15% upside.

Some recent analyst ratings include


Recent Trading Activity for Dova Pharmaceuticals (NASDAQ:DOVA)
Shares of Dova Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version